JULIA L contact HURWITZ

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. ncbi request reprint Epstein-Barr virus vaccine development: a lytic and latent protein cocktail
    Timothy D Lockey
    Department of Immunology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Front Biosci 13:5916-27. 2008
  2. pmc Respiratory tract epithelial cells express retinaldehyde dehydrogenase ALDH1A and enhance IgA production by stimulated B cells in the presence of vitamin A
    Rajeev Rudraraju
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee, United States of America
    PLoS ONE 9:e86554. 2014
  3. pmc Respiratory syncytial virus: current progress in vaccine development
    Rajeev Rudraraju
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Viruses 5:577-94. 2013
  4. pmc Respiratory syncytial virus vaccine development
    Julia L Hurwitz
    Department of Infectious Diseases, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Expert Rev Vaccines 10:1415-33. 2011
  5. ncbi request reprint Application of the polyvalent approach to HIV-1 vaccine development
    Julia L Hurwitz
    Department of Immunology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Curr Drug Targets Infect Disord 5:143-56. 2005
  6. ncbi request reprint HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail
    Julia L Hurwitz
    Department of Immunology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Front Biosci 13:609-20. 2008
  7. doi request reprint Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections
    Julia L Hurwitz
    Department of Infectious Diseases, St Jude Children s Research Hospital, and Department of Pathology, University of Tennessee, Memphis, TN 38105, USA
    Pediatr Infect Dis J 27:S126-8. 2008
  8. ncbi request reprint HIV vaccine rationale, design and testing
    Karen S Slobod
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Curr HIV Res 3:107-12. 2005
  9. pmc Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections
    Xiaoyan Zhan
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, United States
    Vaccine 26:3480-8. 2008
  10. pmc Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV
    Bart Jones
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, United States
    Vaccine 27:1848-57. 2009

Collaborators

  • P C Doherty
  • John Stambas
  • T Takimoto
  • Shan Lu
  • Mattia Bonsignori
  • Yoshiyuki Nagai
  • K S Slobod
  • Rajeev Rudraraju
  • DAVID L contact WOODLAND
  • Xiaoyan Zhan
  • Sherri Surman
  • Scott A Brown
  • Robert Sealy
  • Timothy D Lockey
  • Sherri L Surman
  • Bart Jones
  • Chris Coleclough
  • Allen Portner
  • Bart G Jones
  • Amy Zirkel
  • Charles J Russell
  • Sateesh Krishnamurthy
  • Maxwell Madzikanga
  • Christopher Coleclough
  • Kristen Branum
  • Vicki Traina-Dorge
  • Louis Martin
  • James Blanchard
  • Vasiliy Mishin
  • Timothy Lockey
  • Patricia Flynn
  • Pamela Freiden
  • Nanna Howlett
  • Laura E Luque
  • Clare E Sample
  • Wendy Chaka
  • Peter Cresswell
  • Ruth A Scroggs
  • Kelli Boyd
  • Irina Alymova
  • Abigail Kangwende
  • Vishwajeeth R Pagala
  • James L Blanchard
  • Louis N Martin
  • Clive Slaughter
  • Ashutosh Mishra
  • Robert E Sealy
  • John Pfumojena
  • Stephen W White
  • Scott Brown

Detail Information

Publications34

  1. ncbi request reprint Epstein-Barr virus vaccine development: a lytic and latent protein cocktail
    Timothy D Lockey
    Department of Immunology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Front Biosci 13:5916-27. 2008
    ..Results encourage further development of the cocktail vaccine strategy as a potentially powerful weapon against EBV infection and disease in humans...
  2. pmc Respiratory tract epithelial cells express retinaldehyde dehydrogenase ALDH1A and enhance IgA production by stimulated B cells in the presence of vitamin A
    Rajeev Rudraraju
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee, United States of America
    PLoS ONE 9:e86554. 2014
    ....
  3. pmc Respiratory syncytial virus: current progress in vaccine development
    Rajeev Rudraraju
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Viruses 5:577-94. 2013
    ..The virus is herein described together with the hurdles that must be overcome to develop a vaccine and some current vaccine development approaches...
  4. pmc Respiratory syncytial virus vaccine development
    Julia L Hurwitz
    Department of Infectious Diseases, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Expert Rev Vaccines 10:1415-33. 2011
    ..The development of a successful RSV vaccine may ultimately stem from attention to historical lessons, in concert with an integral partnering of immunology and virology research fields...
  5. ncbi request reprint Application of the polyvalent approach to HIV-1 vaccine development
    Julia L Hurwitz
    Department of Immunology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Curr Drug Targets Infect Disord 5:143-56. 2005
    ..Information presented in this review highlights the potential and importance of the polyvalent vaccine approach for the future development of an effective HIV-1 vaccine...
  6. ncbi request reprint HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail
    Julia L Hurwitz
    Department of Immunology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Front Biosci 13:609-20. 2008
    ..The SJCRH multi-vectored, multi-envelope vaccine has now been shown to elicit HIV-1-specific B- and T-cell functions with a diversity and durability that may be required to prevent HIV-1 infections in humans...
  7. doi request reprint Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections
    Julia L Hurwitz
    Department of Infectious Diseases, St Jude Children s Research Hospital, and Department of Pathology, University of Tennessee, Memphis, TN 38105, USA
    Pediatr Infect Dis J 27:S126-8. 2008
    ..As clinical safety studies progress, St. Jude Children's Research Hospital researchers are also working to formulate a SV-based cocktail vaccine designed to prevent several hPIV and RSV infections in humans...
  8. ncbi request reprint HIV vaccine rationale, design and testing
    Karen S Slobod
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Curr HIV Res 3:107-12. 2005
    ..Here, data relevant to the development of cocktail vaccines, designed to harness diverse, envelope-specific B-cell and T-cell responses, are reviewed...
  9. pmc Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections
    Xiaoyan Zhan
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, United States
    Vaccine 26:3480-8. 2008
    ..Results encourage the continued development of the candidate recombinant SeV vaccines to combat serious respiratory infections of children...
  10. pmc Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV
    Bart Jones
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, United States
    Vaccine 27:1848-57. 2009
    ..Results identify SeV vectors as promising vaccine candidates for four different paramyxoviruses, each responsible for serious respiratory infections in children...
  11. pmc Clearance of HIV type 1 envelope recombinant sendai virus depends on CD4+ T cells and interferon-gamma but not B cells, CD8+ T cells, or perforin
    Sherri L Surman
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    AIDS Res Hum Retroviruses 26:783-93. 2010
    ..Taken together, our results showed that HIV-1 envelope recombinant virus clearance was dependent on CD4(+) T cells and IFN-gamma, but occurred in the absence of B cells, CD8(+) T cells, or perforin...
  12. pmc Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B
    Xiaoyan Zhan
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332N Lauderdale, Memphis, TN 38105, United States
    Vaccine 25:8782-93. 2007
    ..Together, experimental results encourage promotion of this recombinant SV construct as a vaccine candidate for the prevention of RSV in humans...
  13. ncbi request reprint Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity
    Scott A Brown
    Department of Immunology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Immunol 171:4140-8. 2003
    ..To explain the clustering of Th cell epitopes, we propose that localization of peptide on exposed envelope surfaces facilitates proteolytic activity and preferential peptide shuttling through the Ag processing pathway...
  14. pmc A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein
    Scott A Brown
    Department of Immunology, Memphis, TN 38105, USA
    J Virol 81:12535-42. 2007
    ....
  15. ncbi request reprint HIV-1 envelope T cell epitope "hotspots " among mice and humans and among CD4+ and CD8+ T cell subpopulations
    Xiaoyan Zhan
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, Tennessee 38105, USA
    AIDS Res Hum Retroviruses 23:471-6. 2007
    ..These results emphasized the important influence that envelope peptide position may have on antigen processing, and the consequent impact such processing may have on HIV-1-specific CD4(+) and CD8(+) T-cell activities...
  16. ncbi request reprint Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV
    Xiaoyan Zhan
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Vaccine 23:5306-20. 2005
    ..The present report is the first to describe pathogenic SHIV disease control mediated by a heterologous HIV-1 vaccine, devoid of 89.6 or SIV derivatives...
  17. ncbi request reprint Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults
    Karen S Slobod
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Vaccine 22:3182-6. 2004
    ..Results encourage future trials to evaluate the efficacy of Sendai virus in preventing human PIV-1 infection in infants and children...
  18. ncbi request reprint HIV vaccines: brief review and discussion of future directions
    Karen S Slobod
    Department of Infectious Diseases, St Jude Children s Research Hospital, MS 320 332 N Lauderdale, Memphis, TN 38105, USA
    Expert Rev Vaccines 4:305-13. 2005
    ..This article reviews data relevant to the development of cocktail vaccines which have been designed to elicit a wide range of envelope glycoprotein-specific B- and T-cell responses...
  19. ncbi request reprint First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants
    Julia L Hurwitz
    Department of Immunology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    AIDS 22:149-51. 2008
    ..Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant...
  20. ncbi request reprint Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells
    Xiaoyan Zhan
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    Vaccine 22:1206-13. 2004
    ..Our results illustrate the flexibility and durability of immune responses toward individual components of mixed envelope vaccines and encourage the continued development of vaccine cocktails for the control of HIV...
  21. ncbi request reprint CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection?
    Scott A Brown
    Deparment of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Curr Drug Targets Infect Disord 5:113-9. 2005
    ..Since CTL contribute to the success of vaccines in other model systems, an understanding of the strengths and possible limitations of these cells may be critical to future successes in the HIV-1 vaccine field...
  22. pmc Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine
    Robert Sealy
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Int Rev Immunol 28:49-68. 2009
    ..Preliminary analyses demonstrate early proof-of-principle that a multi-envelope vaccine can elicit neutralizing antibody responses toward heterologous HIV-1 in humans...
  23. ncbi request reprint A five-residue HIV envelope helper T cell determinant: does this peptide-MHC interaction leave the binding groove half empty?
    Timothy D Lockey
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    AIDS Res Hum Retroviruses 18:1141-4. 2002
    ..The remaining positions may be empty, or may be associated with a second, perhaps unrelated, peptide moiety...
  24. pmc SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?
    Robert Sealy
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Curr HIV Res 7:497-503. 2009
    ..Perhaps this protective state may serve as a 'gold-standard' for HIV-1 vaccine development, as a similar degree of protection against immunodeficiency virus infections in humans would be much desired...
  25. pmc Short communication: The dead cell: a potent escort for HIV type 1 transinfection
    Robert Sealy
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    AIDS Res Hum Retroviruses 25:1123-8. 2009
    ..The fact that dead cells or membranes can support this activity may explain, at least in part, the high frequency of human HIV-1 infections at sites of tissue damage...
  26. pmc HIV-1 vaccine design: harnessing diverse lymphocytes to conquer a diverse pathogen
    Sherri L Surman
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Hum Vaccin 5:268-71. 2009
    ..Here we describe current efforts to gain insights from other vaccine fields and to adopt a cocktail vaccine approach for the prevention of HIV-1 infections in humans...
  27. pmc Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV
    Toru Takimoto
    St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    J Virol 78:6043-7. 2004
    ..RSV G-recombinant SV is thus a promising live virus vaccine candidate for RSV...
  28. ncbi request reprint A highly sensitive single-cell assay detects T-helper cell responses missed by conventional interleukin-2-based methods
    Sherri Surman
    Department of Immunology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Immunol Methods 260:279-83. 2002
    ....
  29. ncbi request reprint T cell epitope "hotspots" on the HIV Type 1 gp120 envelope protein overlap with tryptic fragments displayed by mass spectrometry
    Scott A Brown
    Department of Immunology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    AIDS Res Hum Retroviruses 21:165-70. 2005
    ..Results are consistent with the suggestion that gp120 peptide location influences antigen processing, which, in turn, influences the specificity of immunodominant T cells...
  30. pmc Target peptide sequence within infectious human immunodeficiency virus type 1 does not ensure envelope-specific T-helper cell reactivation: influences of cysteine protease and gamma interferon-induced thiol reductase activities
    Robert Sealy
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    Clin Vaccine Immunol 15:713-9. 2008
    ..The results highlight potential influences of peptide context on T-cell reactivation by HIV-1 and encourage the continued study of antigen processing as support for improved vaccine design...
  31. pmc Antibody response to influenza infection of mice: different patterns for glycoprotein and nucleocapsid antigens
    Robert Sealy
    Department of Immunology, St Jude Children s Research Hospital, Memphis, TN, USA
    Immunology 108:431-9. 2003
    ..The response towards Sendai virus exhibits neither the early appearance of anti-glycoprotein AFC expressing IgA in draining lymph nodes, nor the subsequent relative deficit of this specificity from bone marrow AFC populations...
  32. ncbi request reprint Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus
    Toru Takimoto
    Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA
    Viral Immunol 18:255-66. 2005
    ..Sendai virus may prove an enormously valuable vaccine platform, permitting the delivery of recombinants targeting important pediatric respiratory pathogens, RSV chief among them...
  33. ncbi request reprint HIV vaccine discovery and development
    Julia L Hurwitz
    Curr Drug Targets Infect Disord 5:81-3. 2005
  34. ncbi request reprint The HIV pandemic: a forgotten crisis?
    Maxwell Madzikanga
    HIV AIDS Programme, Africa University, Old Mutare, Zimbabwe
    Curr Drug Targets Infect Disord 5:85-6. 2005
    ..The devastation caused by HIV and AIDS has touched virtually every world region. One concern is that the unrelenting nature of the HIV pandemic fosters a disposition, not of fear and determination, but of tolerance and complacency...

Research Grants13

  1. Influence of maternal antibodies on a Sendai virus-vectored RSV vaccine
    JULIA L contact HURWITZ; Fiscal Year: 2010
    ..Data from these experiments will have broad application to the pediatric vaccine field, and will be critical to the launch of clinical trials with rSeV-RSV-F. ..
  2. MARROW TRANSPLANT IN CANCER THERAPY--T-CELL RECOVERY
    JULIA HURWITZ; Fiscal Year: 1992
    ....
  3. MARROW TRANSPLANT IN CANCER THERAPY T CELL RECOVERY
    JULIA HURWITZ; Fiscal Year: 2001
    ..Jude Children's Research Hospital (SJCRH), predicting successful implementation of the proposed studies. ..
  4. HIV-envelope-specific CD4+ T-cell activation and functional potentials
    JULIA HURWITZ; Fiscal Year: 2009
    ..Results from these experiments may be invaluable to the construction of new, successful HIV-1 vaccines designed to capture the full potentials of the immune response. ..
  5. DEVELOPMENT OF A NOVEL MULTIENVELOPE AIDS VACCINE
    JULIA HURWITZ; Fiscal Year: 2004
    ..Project 4 (K. Slobod) builds on these studies, initiating clinical trials of the safety and effectiveness of vaccines comprised of combinations of immunogenic envelopes. ..
  6. MARROW TRANSPLANT IN CANCER THERAPY T CELL RECOVERY
    JULIA HURWITZ; Fiscal Year: 2000
    ..Jude Children's Research Hospital (SJCRH), predicting successful implementation of the proposed studies. ..
  7. MARROW TRANSPLANT IN CANCER THERAPY--T-CELL RECOVERY
    JULIA HURWITZ; Fiscal Year: 1993
    ....
  8. MARROW TRANSPLANT IN CANCER THERAPY T CELL RECOVERY
    JULIA HURWITZ; Fiscal Year: 1999
    ..Jude Children's Research Hospital (SJCRH), predicting successful implementation of the proposed studies. ..
  9. HIV-envelope-specific CD4+ T-cell activation and functional potentials
    Julia L Hurwitz; Fiscal Year: 2010
    ..Results from these experiments may be invaluable to the construction of new, successful HIV-1 vaccines designed to capture the full potentials of the immune response. ..